Nano-S1

Nano-S1 is an investigational colloidal silver nanoparticle formulation developed by the General Administration of Military Health in Tunisia. It was evaluated in a Phase 3, randomized, double-blind, placebo-controlled clinical trial (NCT04971226) for the treatment of adult patients with mild to moderate COVID-19 who were at high risk for progression to severe disease. Colloidal silver consists of microscopic silver particles suspended in a liquid medium and has historically been used for its broad-spectrum antimicrobial properties. In the context of SARS-CoV-2 infection, Nano-S1 was investigated for its potential to inhibit viral replication or entry through non-specific interactions with viral proteins or membranes. The treatment protocol in the clinical trial involved oral administration of the suspension over a five-day period.

Other names

colloidal silverargent colloïdal